Purpose Classical Hodgkin lymphoma (HL) frequently exhibits genetic alterations leading to
overexpression of the programmed death-1 (PD-1) ligands, suggesting a possible …

The KEYNOTE-013 study was conducted to evaluate pembrolizumab monotherapy in
hematologic malignancies; classical Hodgkin lymphoma (cHL) was an independent …

Abstract The programmed death-1 (PD-1) pathway serves as an immune checkpoint to
temporarily dampen immune responses upon chronic antigen stimulation. Normal antigen …

Purpose Genetic alterations causing overexpression of programmed death-1 ligands are
near universal in classic Hodgkin lymphoma (cHL). Nivolumab, a programmed death-1 …

Background Malignant cells of classical Hodgkin's lymphoma are characterised by genetic
alterations at the 9p24. 1 locus, leading to overexpression of PD-1 ligands and evasion of …

This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo)
as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma …

Abstract In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo)
administered in combination were evaluated as initial salvage therapy in patients with …

Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24. 1, leading
to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a …

Programmed death-1 inhibitors are approved for patients with relapsed or refractory classic
Hodgkin lymphoma (RRcHL). We present the 2-year follow-up of the phase 2 KEYNOTE …

Background PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity
and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we …